Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | INMT | O95050 | 1/20 | 0.35 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16744219 | 0.77 | KDM4E (0.35) | MEN1GAAKMT2A | |
| SCHEMBL12424583 | 0.77 | CA1 (0.33) | — | |
| SCHEMBL24654710 | 0.77 | ALDH1A1 (0.49) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL15691802 | 0.74 | MEN1 (0.48) | MEN1ALDH1A1GAAKMT2AINMT | |
| SCHEMBL22627563 | 0.69 | MEN1 (0.45) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL10226479 | 0.69 | GAA (0.53) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL19705380 | 0.69 | MEN1 (0.44) | MEN1ALDH1A1GAAKMT2AINMT | |
| SCHEMBL1615688 | 0.68 | DRD2 (0.42) | ALDH1A1GAA | |
| SCHEMBL16746094 | 0.68 | MEN1 (0.36) | MEN1ALDH1A1GAAKMT2AINMT | |
| SCHEMBL16746090 | 0.68 | MEN1 (0.36) | MEN1ALDH1A1GAAKMT2AINMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737516-B2 | Bicyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160213654-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2016-07-28 | — | — | US | disclosed |
| US-9315501-B2 | Bicyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150148375-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148375-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | MEN1 2146/4885ALDH1A1 4585/4885GAA 4778/4885 |
| US-20160213654-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | MEN1 2146/4885ALDH1A1 4585/4885GAA 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.